Rowland & CO Investment Counsel Regeneron Pharmaceuticals, Inc. Transaction History
Rowland & CO Investment Counsel
- $455 Million
- Q2 2024
A detailed history of Rowland & CO Investment Counsel transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Rowland & CO Investment Counsel holds 116 shares of REGN stock, worth $133,779. This represents 0.03% of its overall portfolio holdings.
Number of Shares
116
Previous 116
-0.0%
Holding current value
$133,779
Previous $111,000
9.01%
% of portfolio
0.03%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding REGN
# of Institutions
1,461Shares Held
84.5MCall Options Held
907KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$10.4 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$9.74 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$9.55 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.58 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$5.35 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $124B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...